NV
DICE

Northpond Ventures’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Northpond Ventures’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,292,871
Closed -$94.3M – 5
2023
Q1 		$94.3M Hold
3,292,871
– – 53.91% 1
2022
Q4 		$103M Hold
3,292,871
– – 55.73% 1
2022
Q3 		$66.8M Hold
3,292,871
– – 46.8% 1
2022
Q2 		$51.1M Hold
3,292,871
– – 48.67% 1
2022
Q1 		$63M Hold
3,292,871
– – 33.95% 1
2021
Q4 		$83.3M Buy
+3,292,871
New +$96.5M 29.17% 2

Other funds holding DICE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Northpond Ventures's DICE Position: Q2 2023 in Review

Northpond Ventures sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q2 2023, closing a stake of 3,292,871 shares — an estimated $94.3M sold.

Northpond Ventures first reported a position in DICE in Q4 2021 and held it in 6 quarters. The position peaked at $103M in Q4 2022. 160 funds tracked by Wall St. Rank hold DICE as of Q2 2023.

  • Northpond Ventures reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Northpond Ventures sold 3,292,871 DICE Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $94.3M.
  • Northpond Ventures first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
  • Northpond Ventures's DICE Therapeutics, Inc. Common Stock position peaked at $103M in Q4 2022.
  • 160 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Northpond Ventures's 13F filing for Q2 2023, filed 14 Aug 2023.